Abstract
Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section. Reference 24 needs to be amended to 25 The 12-week study needs to be corrected to 8-week study Corrected text: This study is the first to compare two LAMA/LABA dual therapies using direct head-to-head data from a randomized, 8-week study [25], which is the most reliable set of data to include within a cost-effectiveness model [25].
Cite
CITATION STYLE
Driessen, M. T., Whalen, J., Buguth, B. S., Vallejo-Aparicio, L. A., Naya, I. P., Asukai, Y., … Risebrough, N. A. (2019, January 28). Correction: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective (Respiratory Research (2018) 19 (224) DOI: 10.1186/s12931-018-0916-7). Respiratory Research. BioMed Central Ltd. https://doi.org/10.1186/s12931-019-0985-2
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
